USP22 and cancer: It has been reported to deubiquitinate the intracellular domain of PD‐L1 with a C‐terminal fragment and suppress anticancer immunity in various cancers.[33, 34] However, there is no research indicating whether EZH2 can regulate the stability of the PD‐L1 protein through its effect on USP22 expression.